Venn Life Sciences Holdings Plc FINAL RESULTS For the Year ended 31 December 2014

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces Its audited final results for the year ended 31 December 2014.

Financial Highlights

·         Revenue of €4.9m increase of 140% over 2013 (€2.04m)

·         Group EBITDA Loss (before exceptional items) of €1.53m (2013 €1.65m)

·         Group Loss for the year €1.8m (2013 €1.8m)

·         EBITDA Losses attributable to CRO Business down by 36% to €0.95m (2013 €1.56m)

·         EBITDA Losses attributable to investment in Innovenn €0.58m (2013 €0.09m)

·         Cash and cash equivalents of €0.8m (2013 €0.54m)

Operational Highlights

·         Acquisition of Cardinal Systems France bringing IRT, Data Management and additional clinical capabilities to Venn

·         Resource base increased from 43 to 100 personnel

·         Successful integration of German, Paris and Northern Ireland acquisitions

·         Successful deployment of resources in Mexico, Brazil, Israel and USA  


Post Period End

·         Strong rate of business wins and new proposals continues

·         €4.1m contract secured in March

·         Revenues of €2.0m booked for Q1 2015

·         First Innovenn revenues with sales of Labskin to global pharmaceutical company

·         Board strengthened with two new appointments, Gracielle Schutjens as COO and Jonathan Hartshorn as CFO (effective 15th June 2015)

·         Completion of GBP£2m fundraise underpinning growing book of business and providing funds for systems investment and expansion of business development coverage

Commenting on the Group's outlook, David Evans, Non-Executive Chairman of Venn:

"In 2014 we have seen key financial indicators moving in the right direction. A significant increase in revenues, reduced losses on the core business and a stronger balance sheet all point to real progress and sustainable business growth. The addition of IRT and data management services through the acquisition of Cardinal Systems has been instrumental in Venn winning larger full service contracts as evidenced by the announcement of a €4m contract in March of this year. With a healthy pipeline of project opportunities the business is poised for further growth. This can be strongly underpinned by solid execution of existing contracts, which in turn will result in repeat business.

Although we are still in a period of investment with Innovenn I am particularly pleased to see the first sales of Labskin and greatly encouraged by the calibre of initial customers.  I look forward to progress at Innovenn in 2015 through the addition of microbiology services, the launch of Clarogel and further sales of Labskin."





Venn Life Sciences Holdings Plc

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla Mc Guinness, Marketing Manager

Tel: +353 153 73 269



Zeus Capital (Nominated Adviser and Broker)


Andrew Jones / Ross Andrews

Tel: +44 (0)161 831 1512

Dominic Wilson

Tel: +44 (0)20 7533 7727



Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303




Lianne Cawthorne


020 7933 8788



07584 391 303




Walbrook PR Limited


020 7933 8780

4 Lombard Street


020 7933 8781

London EC3V 9HD


This email is intended only for the use of the addressee named above. The information contained in this message is legally privileged and confidential information intended only for the use of the individual or entity named above. If you, the reader of this message, are not the intended recipient, you are hereby notified that you should not further disseminate, distribute or print this email. In addition, if you have received this message in error, please immediately notify us by telephone and delete it from your system. We apologise for any inconvenience that may have been caused to you.

Please note that Walbrook PR Limited is able to, and reserves the right to, monitor e-mail communications passing through its network.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.